Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22247627 | 0.87 | CYP19A1 (0.48) | CYP19A1HRH4HRH3GGPS1L3MBTL1 | |
| SCHEMBL22062687 | 0.85 | HRH4 (0.47) | POLBKMT2ACYP19A1HRH4HRH3 | |
| SCHEMBL14982736 | 0.83 | CYP19A1 (0.50) | CYP19A1HRH4HRH3GGPS1L3MBTL1 | |
| SCHEMBL1753748 | 0.83 | CYP19A1 (0.61) | CYP19A1HRH4HRH3GGPS1L3MBTL1 | |
| SCHEMBL1345747 | 0.83 | — | — | |
| SCHEMBL16029999 | 0.82 | POLB (0.48) | POLBKMT2ACYP19A1HRH4HRH3 | |
| SCHEMBL19361293 | 0.80 | CYP19A1 (0.45) | CYP19A1HRH4HRH3GGPS1L3MBTL1 | |
| SCHEMBL5021080 | 0.80 | L3MBTL1 (0.56) | CYP19A1HRH4HRH3GGPS1L3MBTL1 | |
| SCHEMBL24713570 | 0.79 | POLB (0.43) | POLBKMT2ACYP19A1HRH4HRH3 | |
| SCHEMBL20615467 | 0.79 | POLB (0.41) | POLBKMT2ACYP19A1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066425-B1 | Oxo-substituted compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| US-20200397927-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| EP-3567029-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | Lantheus Medical Imaging, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-2753605-B1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING INC (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2018102885-A1 | MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2018-06-14 | — | — | WO | disclosed |
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20120309794-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | UNIVERSITÀ DI PISA (IT) | 2012-12-06 | — | — | US | disclosed |
| EP-1874739-B1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | NOVARTIS AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | VCAM1, ICAM1, CD69 | POLB 4451/4885KMT2A 2594/4885CYP19A1 2242/4885 |
| US-11066425-B1 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | POLB 870/4885KMT2A 2610/4885CYP19A1 434/4885 |
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | POLB 3942/4885KMT2A 3430/4885CYP19A1 2566/4885 |
| US-20120309794-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | LDHA, LDHB, DLD | POLB 1490/4885KMT2A 1346/4885CYP19A1 1141/4885 |
| US-20200397927-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | POLB 3942/4885KMT2A 3430/4885CYP19A1 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.